Stoyioglou A, Jaff MR. Medical treatment of peripheral arterial disease: a comprehensive review. J Vasc Interv Radiol. 2004;15:1197-207.

Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001;344:1608-21.

Lastória S, Maffei FHA. Aterosclerose obliterante periférica: epidemiologia, fisiopatologia, quadro clínico e diagnóstico. Doenças vasculares periféricas. 2002:1007-24.

DATASUS. SIM: Sistema de Informação sobre Mortalidade. 2007.

Core health indicators 2002. .

Bhatt DL, Steg PG, Ohman EM. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180-9.

Norgren L, Hiatt WR, Dormandy J, Nehler M, Harris K, Fowkes F. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33:S1-75.

Hirch AT, Criqui MH, Treat-Jacobson D. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317-24.

Nygard O, Vollset SE, Refsum H, Brattström L, Ueland PM. Total homocysteine and cardiovascular disease. J Intern Med. 1999;246:425-54.

McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111-28.

Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med. 1994;236:603-17.

Rassoul F, Richter V, Janke C. Plasma homocysteine and lipoprotein profile in patients with peripheral arterial occlusive disease. Angiology. 2000;51:189-96.

Selhub J. Homocysteine metabolism. Annu Rev Nutr. 1999;19:217-46.

Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transulfuration of homocysteine. Am J Clin Nutr. 1992;55:131-8.

Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 1993;39:1764-79.

Kang SS, Wong PWK, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 1992;12:279-98.

Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995;274:1049-57.

Venancio LS. Indicadores nutricionais e níveis de homocisteína em pacientes com doença arterial periférica. .

Mölgaard J, Malinow MR, Lassvik C, Holm AC, Upson B, Olsson AG. Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication. J Intern Med. 1992;231:273-9.

Malinow MR, Kang SS, Taylor LM. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation. 1989;79:1180-8.

Brattström L, Israelson B, Norrving B. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Atherosclerosis. 1990;81:51-60.

Tsai MY, Arnett DK, Eckfeldt JH, Willians RR, Ellison RC. Plasma homocysteine and its association with carotid intimal-medial wall thickness and prevalent coronary heart disease. Atherosclerosis. 2000;151:519-24.

Brunelli T, Prisco D, Fedi S. High prevalence of mild hyperhomocysteinemia in patients with abdominal aortic aneurysm. J Vasc Surg. 2000;32:531-6.

Tavares JR, D'Almeida V, Diniz DC. Analysis of plasma homocysteine levels in patients with unstable angina. Arq Bras Cardiol. 2002;79:167-72.

Taddei CFG, Batlouni M, Sarteschi C. Hiper-homocisteinemia como fator de risco para doença aterosclerótica coronariana em idosos. Arq Bras Cardiol. 2005;85:166-73.

Faria-Neto JR, Chagas ACP, Bydlowski SP. Hyperhomocysteinemia in patients with coronary artery disease. Braz J Med Biol Res. 2006;39:435-63.

Garófolo L, Barros Junior N, Ferreira SRG, Sanudo A, Miranda Junior F. Moderate hyperhomocysteinemia in atherosclerotic peripheral arterial disease in the diabetics Nipo-Brazilian population in the city of Bauru. J Vasc Bras. 2003;2(^sSuppl 1):S82.

Miranda Junior F, Garófolo L, Barros Junior N, Ferreira SRG, Sanudo A. Influence of gender in a association between moderate hyperhomocysteinemia and peripheral arterial disease in diabetics Nipo-Brazilian in the city of Bauru. J Vasc Bras. 2003;2(^sSuppl 1):S82.

Graham IM, Daly LE, Refsum H. Homocisteína plasmática como fator de risco para doença cardiovascular. JAMA. 1997;277:1775-81.

Nicoloff AD, Taylor LM, Sexton GJ. Relationship between site of initial symptoms and subsequent progression of disease in a prospective study of atherosclerosis progression in patients receiving long-term treatment for symptomatic peripheral arterial disease. J Vasc Surg. 2002;35:38-47.

Taylor LM, De Frang RD, Harris Junior EJ, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg. 1991;13:128-36.

Taylor LM, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg. 1999;29:8-21.

Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-8.

Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost. 1999;81:165-76.

Frosst P, Blom HJ, Milos R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-3.

Verhoeff BJ, Trip MD, Prins MH, Kastelein JJP, Reitsma PH. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. Atherosclerosis. 1998;141:161-6.

Arruda VR, Von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation Ala 677 ® Val in the methylenetetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost. 1997;77:818-21.

Muniz MTC. Avaliação do polimorfismo genético para MTHFR (metilenotetrahidrofolato redutase) e sua correlação com os níveis de homocisteína em pacientes com doença arterial coronariana. .

Jacques PF, Bostom AG, Williams RR. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7-9.

Harker LA, Slichter SJ, Scott CR, Ross R. Homocysteinemia, vascular injury and arterial thrombosis. N Engl J Med. 1974;291:537-43.

Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 1976;58:731-41.

França LHG, Pereira AH, Perini SC. Aterogênese em artéria ilíaca comum de suínos submetidos à homocisteinemia induzida pela ingestão de metionina. J Vasc Bras. 2006;5:11-6.

Stahlke Junior HJ, França LHG, Stahlke PH, Stalhke PS. Hiper-homocisteinemia causando aterogênese na aorta de coelhos-modelo experimental. J Vasc Bras. 2004;3:20-30.

Cerqueira NF, Yoshida WB. Óxido nítrico: Revisão. Acta Cir Bras. 2002;17:417-23.

Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost. 2005;8:1646-54.

Blom HJ. Consequences of homocysteine export and oxidation in the vascular system. Semin Thromb Haemost. 2000;26:227-32.

Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Diff. 2004;11:S56-64.

Poddar R, Sivasubramanian N, Dibello PM, Robinson K, Jacobsen DW. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: Implications for vascular disease. Circulation. 2001;103:2717-23.

Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-9.

Graham IM, O'Callaghan P. Vitamins, homocysteine and cardiovascular risk. Cardiovasc Drugs Ther. 2002;16:383-9.

Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-8.

Durand P, Prost M, Loreau N, Lussier-Cacan A, Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest. 2001;81:645-72.

Merchant AT, Hu FB, Spiegelman D, Willet WC, Rimm EB, Ascherio A. The use of B vitamin supplements and peripheral arterial disease risk in men are inversely related. J Nutr. 2003;133:2863-7.

USDA Nutrient Database for Standard Reference, Release 11. .

Dietary Reference Intakes (DRI) for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and coline. 2000.

Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449-54.

Malinow MR, Duell PB, Hess DL. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med. 1998;338:1009-15.

Guia alimentar para a população brasileira: promovendo a alimentação saudável. Referencial teórico - Deficiências nutricionais. 2005:20.

Farinha terá ácido fólico para combater anencefalia em bebês. 2002.

Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. BMJ. 1998;316:894-8.

Brouwer IA, van Dusseldorp M, West CE. Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. J Nutr. 1999;129:1135-9.

Riddell LI, Chisholm A, Williama S, Mann JI. Dietary strategies for lowering homocysteine concentrations. Am J Clin Nutr. 2000;71:1448-54.

Venn BJ, Mann JI, Williams SM. Dietary counseling to increase natural folate intake: a randomized, placebo-controlled trial in free-living subjects to assess effects on serum folate and plasma total homocysteine. Am J Clin Nutr. 2002;76:758-65.

Venâncio LS, Santos MDB, Yoshida WB. Efeitos da suplementação vitamínica de ácido fólico, vitamina B12 e vitamina B6 sobre a concentração de homocisteína em indivíduos portadores de doença arterial periférica. J Vasc Bras. 2003;2(^sSuppl 1):S83.

Pereira AF. Efeito da suplementação de ácido fólico e do exercício físico sobre as concentrações de homocisteína plasmática em indivíduos portadores de hipertensão arterial essencial. .

Omenn GS, Beresford SAA, Motulsky AG. Preventing coronary heart disease: B vitamins and homocysteine. Circulation. 1998;97:421-4.

Kuller LH, Evans RW. Homocysteine, vitamins and cardiovascular disease. Circulation. 1998;98:196-9.

Brevetti G, Silvestro A, Di Giacomo S. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg. 2003;38:374-9.

Chambers JC, Ueland PM, Obeid OA, Wrigley J, Refsum H, Kooner JS. Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine. Circulation. 2000;120:2479-83.

Title LM, Cummings PM, Giddens K, Genest JJ, Nassar BA. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol. 2000;36:758-65.

Thambyrajah J, Landray MJ, Jones HJ, Mcglynn FJ, Wheeler DD, Townend JN. A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. J Am Coll Cardiol. 2001;37:1858-63.

Bellamy MF, Mcdowell IFW, Ramsey NM, Brownlee M, Newcombe RG, Lewis MJ. Oral folate enhances endothelial function in hyperhomocystaemic subjects. Eur J Clin Invest. 1999;29:659-62.

Usui M, Matsuoka H, Miyzaki H, Ueda S, Okuda S, Imaizumi T. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid. Clin Sci. 1999;96:235-9.

Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia. J Am Coll Cardiol. 1999;34:2002-6.

Smith TP, Cruz CP, Brown AT, Eidt JF, Moursi MM. Folate supplementation inhibits intimal hyperplasia induced by a high-homocysteine diet in a rat carotid endarterectomy model. J Vasc Surg. 2001;34:474-81.

Lee H, Kim J, Kim HJ, Lee I, Chang N. Folic acid supplementation can reduce the endothelial damage in rat brain microvasculature due to hyperhomocysteinemia. J Nutr. 2005;135:544-8.

Schnyder G, Roffi M, Pin R. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001;345:1593-600.

Durga J, van Tits LJH, Schooten EG. Effect of lowering of homocysteine levels on inflammatory markers: A randomized controlled trial. Arch Intern Med. 2005;165:1388-94.

Schernthaner GH, Plank C, Minar E. No effect of homocysteine-lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease. Eur j Clin Invest. 2006;36:333-9.

Bunout D, Garrido A, Suazo M. Effects of supplementation with folic acid and antioxidant vitamins on homocysteine levels and LDL oxidation in coronary patients. Nutrition. 2000;16:107-110.

De Jong SC, Stehouwer CDA, Van Den Berg M, Geurts TW, Bouter LM, Rauwerda JA. Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease: A prospective cohort study. J Intern Med. 1999;246:87-96.

Vermeulen EGJ, Stehouwer CDA, Twisk JWR. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomized, placebo-controlled trial. Lancet. 2000;355:517-22.

Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol. 2003;41:2105-13.

Toole JF, Malinow MR, Chambless LE. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The vitamins intervention for stroke prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-75.

Nallamothu BK, Fendrick AM, Rubenfire M, Saint S, Bandekar RR, Omenn GS. Potential clinical and economic effects of homocysteine lowering. Arch Intern Med. 2000;160:3406-12.

Tice JA, Ross E, Coxson PG. Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: Effect of grain fortification and beyond. JAMA. 2001;286:936-43.

Lonn E. Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction?. 2007;14:481-7.

Homocysteine and cardiovascular disease: a review of the evidence. 2007;4:143-50.

Hansrani M, Stansby G. Homocysteine lowering interventions for peripheral arterial disease and bypass grafts. Cochrane Database Syst Rev. 2002.

Khandanpour N, Loke YK, Meyer FJ, Jennings B, Armon MP. Eur J Vasc Endovasc Surg. 2009;38(3):316-22.

McCully KS. Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr. 2007;86:1563S-8S.